Could a drug make stem cell transplants safer for myelofibrosis patients?
NCT ID NCT04384692
First seen Oct 31, 2025 · Last updated May 17, 2026 · Updated 28 times
Summary
This study tests whether giving the drug ruxolitinib before, during, and after a donor stem cell transplant can help prevent graft-versus-host disease (GVHD) in people with myelofibrosis. About 53 adults with intermediate- or high-risk myelofibrosis will receive ruxolitinib to reduce inflammation and improve transplant success. The goal is to lower GVHD risk and improve survival and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.